Stem Cell Engraftment via Controlled Micro-Inflammatory Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for using mesenchymal stem cells (MSCs) to repair tissues are inefficient and impractical, as they often require gross tissue injury to signal MSC homing, and existing injectable hyperosmolar substances have limited success in clinical settings.
Innovation Solution
A composition combining cell growth enhancing agents, such as platelet rich fibrin solutions and recombinant growth factors, with inflammation inducing agents like osmolar agents and inflammatory cytokines, to facilitate tissue repair without initial gross injury, along with the optional administration of stem cells to the repair site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gross tissue injury is used to signal MSC homing, then stem cells migrate to the injury site, but the approach causes more damage than actual repair and is impractical for clinical care
Solution Approach 1:
The patent converts the harmful effect of gross tissue injury into a beneficial signal by using controlled, localized injury mechanisms. Instead of causing extensive damage to signal MSC homing, the invention uses targeted approaches that create minimal injury sufficient to trigger the homing response while avoiding excessive tissue damage. This transforms the harmful injury signal into a controlled therapeutic tool.
Solution Approach 2:
The patent introduces intermediary substances and methods between the injury signal and MSC homing. Rather than relying directly on gross tissue injury, the invention uses intermediate mediators such as growth factors, cytokines, or controlled delivery systems that translate minimal injury signals into effective MSC recruitment without requiring extensive tissue damage.
2Reliability
If injectable hyperosmolar substances are used to initiate tissue injury and prompt healing, then some healing response is achieved, but the procedures have limited practical success in the health care setting
Solution Approach 1:
The patent optimizes parameters of hyperosmolar substance injection by controlling concentration, volume, injection pressure, and timing. Rather than using fixed protocols, the invention adjusts these parameters to achieve optimal tissue response while minimizing adverse effects, thereby improving clinical success rates. This includes optimizing the osmolar concentration to trigger sufficient injury response without causing excessive damage.
Solution Approach 2:
The patent introduces dynamic control to the injection process, allowing adjustment of injection parameters based on real-time patient response and tissue characteristics. The treatment protocol adapts to individual patient needs, modifying injection parameters dynamically to optimize healing response while reducing the risk of complications, thereby improving overall clinical productivity and success rates.
3Ease of operation
If mere implantation of stem cells is performed through minimally invasive procedures, then the procedure is simple and minimally invasive, but the implantation has proven mostly ineffective
Solution Approach 1:
The patent applies preliminary action by preparing the tissue site before stem cell implantation. This includes pre-conditioning the target tissue through controlled injury signals, growth factor delivery, or inflammatory modulation to create an optimal environment for stem cell engraftment. By preparing the site in advance, the procedure maintains minimally invasive characteristics while significantly improving the effectiveness of stem cell implantation.
Solution Approach 2:
The patent uses composite delivery systems that combine stem cells with supportive materials such as growth factors, scaffolds, or protective carriers. This composite approach enhances stem cell survival and integration while maintaining minimally invasive delivery methods. The composite material provides a protective and supportive environment that improves engraftment effectiveness without requiring more invasive surgical procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively induces local tissue repair and replacement by creating a micro-inflammatory response and enhancing cell growth, improving the practicality and effectiveness of MSC implantation in a minimally invasive manner.
Implementation Method 1
injectable hyperosmolar substances that initiate tissue injury
Implementation Method 2
cell growth enhancing compositions can include an autologous composition spiked with one or more non-autologous factors. Typical non-autologous growth compositions include recombinant growth factors
Implementation Method 3
inflammation inducing agents include agents that induce local micro-diffuse injury at the site in need of repair and include osmolar agents, inflammatory cytokines
Data Source
AI summary
Tissue repair in-vivo depends on acute inflammation, but in many clinical situations the other major components of healing such as blood supply, anabolic hormones, growth factors, and stem cells are lacking. This invention includes compositions consisting of an agent which induces an inflammatory healing response combined with an autologous platelet lysate at a specific concentration which may have demonstrated in-vitro abilities to expand autologous tissue repair cells.